Deep-pocketed investors have adopted a bullish approach towards Sarepta Therapeutics (NASDAQ:SRPT), and it's something market players shouldn't ignore. Our tracking of public options records at ...

There are 956 funds or institutions reporting positions in Sarepta Therapeutics ... the author and do not necessarily reflect those of Nasdaq, Inc. Fintel is a leading provider of financial ...

12 analysts have shared their evaluations of Sarepta Therapeutics (NASDAQ:SRPT) during the recent three months, expressing a mix of bullish and bearish perspectives. The table below offers a ...

One of Sarepta's biggest challengers is Solid Biosciences (NASDAQ: SLDB). Below are the details on what has transpired recently surrounding ELEVIDYS. Solid Biosciences may have an opportunity to ...

It has been about a month since the last earnings report for Sarepta Therapeutics (SRPT). Shares have lost about 30.3% in that time frame, underperforming the S&P 500. Will the recent negative ...

Sarepta Therapeutics (NASDAQ:SRPT) has been analyzed by 18 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent ...

The price trend for Sarepta Therapeutics (SRPT) has been bearish lately and the stock has lost 9% over the past four weeks. However, the formation of a hammer chart pattern in its last trading ...

Sarepta Therapeutics SRPT shares soared 8.7% in the last trading session to close at $79.97. The move was backed by solid volume with far more shares changing hands than in a normal session.

SAREPTA THERAPEUTICS ($SRPT) posted quarterly earnings results on Wednesday, February 26th. The company reported earnings of $1.50 per share, missing estimates of $1. ...

Investors with significant funds have taken a bearish position in Sarepta Therapeutics (NASDAQ:SRPT), a development that retail traders should be aware of. This was brought to our attention today ...

The projected annual revenue for Sarepta Therapeutics is 3,480MM ... of the author and do not necessarily reflect those of Nasdaq, Inc. Fintel is a leading provider of financial data and insights ...

Sarepta Therapeutics Background Information ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Fintel is a leading provider of financial data and insights for ...